The evolving role of radiotherapy in oligometastatic pancreatic cancer: from palliation to disease-modifying multidisciplinary integration.
Oligometastatic pancreatic ductal adenocarcinoma (PDAC) may benefit from aggressive multidisciplinary therapy, yet the role of stereotactic body radiotherapy (SBRT) remains controversial and frameworks for patient select Jiarui Zhang and Siming Shi contributed equally to this work. Full text review required for further details.
Oligometastatic pancreatic ductal adenocarcinoma (PDAC) may benefit from aggressive multidisciplinary therapy, yet the role of stereotactic body radiotherapy (SBRT) remains controversial and frameworks for patient select Jiarui Zhang and Siming Shi contributed equally to this work. Full text review required for further details.
What the study was
- Study design
- Diagnostic Validation Study
- Population
- Patient/participant population (size not extracted)
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Frontiers in oncology
Why it surfaced
Scored 8/10 (Diagnostic Validation Study; novelty=2, relevance=3, design_quality=2, population_or_unmet_need=1). HIGH priority by score. Flag corrected from EARLY_CANCER_DETECTION: paper concerns treatment/resistance, not primary cancer screening/detection.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.